Madrigal Q2 Rezdiffra sales rise 71% to $364.3 million; net loss widens to $57.9 million
Madrigal Pharmaceuticals reported second-quarter 2026 net revenue of $364.3 million, up 71% from $212.8 million a year earlier, driven by higher U.S. demand for Rezdiffra. The net loss widened to $57.9 million, or $1.99 per share, from $42.3 million, or $1.50 per share, with a $25.0 million one-time upfront business development expense included. Operating expenses rose to $420.6 million, and cash and marketable securities totaled $838.9 million as of June 30, 2026.
Key points
- Q2 2026 net revenue was $364.3 million, up 71% from $212.8 million in the prior-year quarter.
- Q2 2026 net loss was $57.9 million, or $1.99 per share, versus $42.3 million, or $1.50 per share, a year earlier.
- The net loss included a $25.0 million one-time upfront business development expense, or $0.86 per share.
- Cash, cash equivalents, restricted cash and marketable securities were $838.9 million at June 30, 2026, versus $988.6 million at Dec. 31, 2025.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.